These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 12817518

  • 1. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients.
    Yates CR, Zhang W, Song P, Li S, Gaber AO, Kotb M, Honaker MR, Alloway RR, Meibohm B.
    J Clin Pharmacol; 2003 Jun; 43(6):555-64. PubMed ID: 12817518
    [Abstract] [Full Text] [Related]

  • 2. Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation.
    Azarpira N, Aghdaie MH, Behzad-Behbahanie A, Geramizadeh B, Behzadi S, Malekhoseinie SA, Raisjalal GH, Rahsaz M, Pourgholami A, Sagheb F.
    Exp Clin Transplant; 2006 Jun; 4(1):416-9. PubMed ID: 16827636
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.
    Hu YF, Qiu W, Liu ZQ, Zhu LJ, Liu ZQ, Tu JH, Wang D, Li Z, He J, Zhong GP, Zhou G, Zhou HH.
    Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1093-8. PubMed ID: 17042920
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients.
    Qiu XY, Jiao Z, Zhang M, Zhong LJ, Liang HQ, Ma CL, Zhang L, Zhong MK.
    Eur J Clin Pharmacol; 2008 Nov; 64(11):1069-84. PubMed ID: 18636247
    [Abstract] [Full Text] [Related]

  • 8. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes.
    Hesselink DA, van Gelder T, van Schaik RH, Balk AH, van der Heiden IP, van Dam T, van der Werf M, Weimar W, Mathot RA.
    Clin Pharmacol Ther; 2004 Dec; 76(6):545-56. PubMed ID: 15592326
    [Abstract] [Full Text] [Related]

  • 9. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
    Mouly SJ, Matheny C, Paine MF, Smith G, Lamba J, Lamba V, Pusek SN, Schuetz EG, Stewart PW, Watkins PB.
    Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
    [Abstract] [Full Text] [Related]

  • 10. Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia.
    Cvetković M, Zivković M, Bundalo M, Gojković I, Spasojević-Dimitrijeva B, Stanković A, Kostić M.
    Ther Drug Monit; 2017 Dec; 39(6):589-595. PubMed ID: 29135906
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects.
    Min DI, Ellingrod VL, Marsh S, McLeod H.
    Ther Drug Monit; 2004 Oct; 26(5):524-8. PubMed ID: 15385835
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients.
    Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, Malaise J, Lison D, Squifflet JP, Wallemacq P.
    Pharmacogenetics; 2004 Mar; 14(3):147-54. PubMed ID: 15167702
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem.
    Wang Y, Wang C, Li J, Wang X, Zhu G, Chen X, Bi H, Huang M.
    Eur J Clin Pharmacol; 2009 Mar; 65(3):239-47. PubMed ID: 18936931
    [Abstract] [Full Text] [Related]

  • 18. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients.
    Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ.
    Pharmacogenetics; 2003 Feb; 13(2):89-95. PubMed ID: 12563178
    [Abstract] [Full Text] [Related]

  • 19. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients.
    von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW.
    Clin Chem; 2001 Jun; 47(6):1048-52. PubMed ID: 11375290
    [Abstract] [Full Text] [Related]

  • 20. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies.
    Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J, Schuetz E, Lim R, Lim HL, Ong AB, Lee HS.
    J Clin Oncol; 2002 Sep 01; 20(17):3683-90. PubMed ID: 12202670
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.